ArticleDiscover oncology2026
Multi-omics analysis suggests ZDHHC18 as a potential risk factor for clear cell renal cell carcinoma linked to myeloid DC morphology.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundProtein palmitoylation, a key posttranslational modification, is involved in cell signaling, protein stability, and tumor immune microenvironment (TIME) regulation. ZDHHC3 is known to mediate clear cell renal cell carcinoma (ccRCC) immune evasion by enhancing PD-L1 stability, but the roles of other palmitoyltransferases in ccRCC remain unclear. In this study, we analyzed genomic and transcriptomic data via a multiomics approach to investigate the expression patterns and potential regulatory mechanisms of known palmitoylation enzymes in ccRCC.
methodBy integrating multiple large-scale data sets from GEO, GWAS, and the eQTLGen Alliance, we systematically screened differentially expressed palmitoylated genes using differentially expressed genes (DEG) analysis, two-sample Mendelian randomization (MR) analysis, SMR analysis based on pooled data, mediated Mendelian randomization analysis, and single-cell RNA sequencing technology, and deeply analyzed their potential causal association with renal clear cell carcinoma (ccRCC) and its possible mediating factors. Finally, this study further explored the specific expression patterns of these genes in tumor tissues, providing new perspectives and potential targets for understanding the molecular mechanisms of ccRCC.
resultsDEG analysis revealed that 15 palmitoylation enzymes were abnormally expressed in ccRCC tissues. Both MR and SMR analyses suggested a potential causal association between higher ZDHHC18 expression and an increased risk of ccRCC. Mediation MR analysis further revealed that the forward scatter area (FSC-A) phenotype of myeloid dendritic cells (mDCs) was a potential mediating factor between ZDHHC18 and ccRCC (mediation effect: 12.3%). Single-cell RNA sequencing data indicated a high expression of ZDHHC18 in tumor-infiltrating dendritic cells.
conclusionsThis multi-omics analysis shows the specific overexpression of ZDHHC18 in tumor tissue DCs and suggests it may function by potentially modulating the FSC-A phenotype of mDCs, thereby potentially contributing to ccRCC pathogenesis. These findings provide new directions for discovering novel therapeutic targets for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.